Celcuity Inc Stock Price, News & Analysis

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced the timing for its Q1 2025 financial results release. The company will release its results after market close on Wednesday, May 14, 2025, followed by a management-hosted webcast and conference call at 4:30 p.m. Eastern Time. Domestic participants can dial 1-800-717-1738, while international callers should use 1-646-307-1865. A live webcast will be available, and a replay will be accessible on Celcuity's website after the event.

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has announced its participation in two upcoming investor conferences in April 2025.

CEO and Co-founder Brian Sullivan will present at:

• The Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:00 a.m. ET
• The 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025, at 11:00 a.m. ET

Both presentations will be available via live webcast and can be accessed through the company's investor relations website, with replays available after the events.

Celcuity Inc. (NASDAQ: CELC) reported its Q4 and full year 2024 financial results, highlighting several upcoming clinical milestones. The company's VIKTORIA-1 Phase 3 trial's PIK3CA wild-type cohort is set to report topline data in Q2 2025, while the VIKTORIA-2 Phase 3 trial's first patient enrollment is expected in Q2 2025.

Financial highlights include:

• Q4 2024 net loss of $36.7 million ($0.85 per share)
• Full year 2024 net loss of $111.8 million ($2.83 per share)
• R&D expenses increased to $33.5 million in Q4 2024
• Cash position of $235.1 million expected to fund operations through 2026

The company presented encouraging preliminary overall survival data from their Phase 1b study of gedatolisib combination therapy at the 2024 SABCS, showing median overall survival of 77.3 months in treatment-naïve patients and 33.9 months in previously treated patients.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced it will release its Q4 and full year 2024 financial results after market close on Monday, March 31, 2025.

The company will host a webcast/conference call at 4:30 p.m. Eastern Time on the same day, where management will discuss the results and provide a corporate update. Domestic participants can dial 1-800-717-1738, while international callers should use 1-646-307-1865 to join the teleconference.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced its participation in two upcoming investor conferences.

Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will represent the company at both events where he will present and be available for one-on-one investor meetings.

The first appearance will be a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, at 10:30 a.m. ET. The second presentation will take place at the Leerink Global Healthcare Conference 2025 in Miami on Wednesday, March 12, 2025, at 9:20 a.m. ET.

Live webcasts of both presentations will be available through dedicated weblinks provided in the announcement.

Celcuity (CELC) announced overall survival (OS) data from a Phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy for HR+, HER2- advanced breast cancer. The study showed promising results with a median OS of 77.3 months in treatment-naïve patients and 33.9 months in patients previously treated with CDK4/6 inhibitors.

The data was presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The trial results support Celcuity's clinical development strategy of simultaneously blocking ER, CDK4/6, and PAM signaling pathways, which forms the basis for their ongoing VIKTORIA-1 and planned VIKTORIA-2 Phase 3 trials.

Celcuity Inc. (CELC) announced its Q3 2024 financial results and corporate updates. The company reported 100% enrollment completion for the PIK3CA wild-type cohort in the Phase 3 VIKTORIA-1 trial, with topline data expected in late Q1 2025 or Q2 2025. The PIK3CA mutant cohort data is anticipated in H2 2025. Financial highlights include $264.1 million in cash and investments, expected to fund operations through 2026. Q3 operating expenses were $30.1 million, with a net loss of $29.8 million ($0.70 per share). R&D expenses increased to $27.6 million, primarily due to clinical trial activities and increased personnel costs.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on oncology targeted therapies, has announced upcoming presentations at two major investor conferences. CEO and Co-founder Brian Sullivan will participate in fireside chats at the Stifel 2024 Healthcare Conference on November 19 at 1:15 p.m. ET and the Jefferies London Healthcare Conference on November 21 at 11:30 a.m. GMT/6:30 a.m. ET. Both events will feature live webcasts and one-on-one investor meetings.

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has announced it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. The company will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss results and provide a corporate update. Domestic callers can dial 1-800-717-1738, while international callers should use 1-646-307-1865 to participate.